Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

Ardentia Ltd Ardentia has been providing world class business intelligence solutions to healthcare organisations since 1990. During this time we’ve gained a wealth of experience and a great ...

Kearney Urology Center in the US has reported a 50% reduction in biopsies since adopting a new prostate cancer blood test with “unprecedented accuracy”. The test, EpiSwitch PSE, is the culmination of ...

Novo Nordisk has announced an investment of 8.5bn Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, which ...

Social 360 Social360 are a specialist social media monitoring provider. We combine our own search technology with comms experienced editors, who produce actionable reports at a frequency an in-house ...

BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab-jsgr) has been granted approval by the US Food and Drug Administration (FDA) as part of a first-line combination treatment for advanced gastric cancer.

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate in a deal worth over $2bn. The agreement gives Merck a ...

Amgen’s Imdylltra (tarlatamab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with small cell lung cancer (SCLC). The drug has been specifically ...